Admedus Ltd
ABN 35 088 221 078

REGISTERED OFFICE:
Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879
East Perth Western Australia 6892

T +61 (0)8 9266 0100
F +61 (0)8 9266 0199

E info.au@admedus.com

www.admedus.com

ASX RELEASE

ADMEDUS EXPANDS MARKET FOR ADAPT® TISSUE PRODUCTS

- Admedus develops dura mater repair tissue product
- Initial results very positive with no post-operative issues and early tissue regeneration
- Potential in significant spinal cord and traumatic brain injury treatment markets

Brisbane, Australia, April 6th, 2015

Admedus Limited (ASX: AHZ) today announced successful initial results from a pre-clinical study of ADAPT® treated tissue in the repair of dura mater. Admedus will be progressing this programme into the next study as it advances the product towards market approval.

The study investigated the use of ADAPT® tissue in the repair of dura mater. The results demonstrated excellent post-operative responses with no longer term negative outcomes, no fluid leakage or post-operative infections, while proving to be an excellent replacement for surgical procedures.

"Expansion of our regenerative tissue portfolio into dura mater repair is an exciting and important step in the development and growth of Admedus," said Admedus CEO Lee Rodne.

"With the commercial success that we're achieving with our lead product CardioCel®, it's now an opportune time to expand our regenerative tissue portfolio into additional large target repair markets such as dura mater repairs" he added.

The dura mater is the outer membrane enveloping the brain and spinal cord which is often damaged during traumatic brain injuries (TBI). In the US alone, it is estimated that there are almost 1.7 million traumatic brain injuries each year, with the Centre for Disease Control estimating around 275,000 hospitalisations per annum.

The initial results of Admedus' pre-clinical study showed that after one month post implantation, the ADAPT® treated tissue repairs demonstrated:

- No signs of post-operative infection
- No leakage of cerebrospinal fluid (CSF)
- No signs of post-operative chemical meningitis
- No signs of tissue rejection

Post-operative infections, CSF leakage, meningitis and tissue rejection are all issues which affect the existing, on-market products used in the repair of dura mater, and the results of this study show the potential of the product in the market. ADAPT® treated tissue has the added benefit of being ready to use off the shelf without the need for pre-implant preparation or rehydration. Furthermore, after one month, the repairs showed the initial stages of integration into and around the implanted ADAPT® treated tissue, a key factor in the longer term treatment of patients who have undergone dura mater repair.

Admedus will complete additional histology studies on the explanted tissues while progressing to the next study to support a product regulatory filing for market approval. Additional study data will be prepared for presentation at a conference in the future.

"These initial results are very encouraging and show the potential for ADAPT® tissue engineered dura mater in this market," added Mr Rodne. "The results are consistent with what we already know about ADAPT® treated tissue, with its improved biocompatibility, strength and handling properties combining to give this product a definite edge in the dura mater repair market"

The latest study was undertaken in conjunction with Charles Sturt University in Wagga Wagga and a neurosurgeon from Melbourne University.

Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus

For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454

Media:
Haley Price
+61 (0) 423 139 163
hprice@admedus.com

Media Europe & Asia
Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group lead by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About Admedus Regen

Admedus Regen started as a research programme in 2001, focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT® Tissue Engineering Process. The lead programme, CardioCel®, is approved in Europe, Asia, the US and Canada and is being used in Australia under the Authorised Prescriber Scheme.

Admedus Regen is based on the patented ADAPT® Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT® technology is used to process xenograft tissues to produce unique, implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post-implantation, and has the potential to replace many of the products that surgeons currently use for soft tissue repair.